Five-year outcomes of the PROVE-IT randomized controlled trial: Patient-Reported Outcomes of Robotic vs. Laparoscopic Ventral Hernia Repair with Intraperitoneal Mesh - Scorecard - MDSpire
Advertisement
Five-year outcomes of the PROVE-IT randomized controlled trial: Patient-Reported Outcomes of Robotic vs. Laparoscopic Ventral Hernia Repair with Intraperitoneal Mesh
Clinical Scorecard: Long-term Results from the PROVE-IT Randomized Controlled Trial: Comparing Patient-Reported Outcomes of Robotic and Laparoscopic Approaches to Ventral Hernia Repair Using Intraperitoneal Mesh
At a Glance
Category
Detail
Condition
Ventral Hernia Repair
Key Mechanisms
Comparison of robotic and laparoscopic approaches using intraperitoneal mesh.
Target Population
Patients undergoing ventral hernia repair with midline hernias measuring 7 cm or less.
Care Setting
Single-center randomized controlled trial.
Key Highlights
Comparable 30-day outcomes for robotic and laparoscopic approaches.
Laparoscopic repairs showed lower quality of life at 1 year despite lower hernia recurrence rates.
5-year follow-up aimed to assess long-term patient-reported outcomes.
Patient-reported outcomes measured included quality of life, pain intensity, and bulging.
Clinical recurrence defined by physical examination and imaging.
Guideline-Based Recommendations
Diagnosis
Clinical hernia recurrence identified through physical examination and cross-sectional imaging.
Management
Robotic and laparoscopic approaches are both viable for ventral hernia repair.
Monitoring & Follow-up
Patient-reported outcomes should be collected at 5 years post-operation.
Risks
Potential for clinical hernia recurrence and need for reoperations.
Patient & Prescribing Data
Patients with midline ventral hernias measuring 7 cm or less.
Both robotic and laparoscopic techniques are used with intraperitoneal mesh.
Clinical Best Practices
Utilize validated surveys for assessing patient-reported outcomes.
Conduct thorough follow-up assessments including physical exams and imaging.
by Erika M. Schmidt, William C. Bennett, Noah X. Tocci, Alvaro C. Carvalho, Cammy Tang, Chao Tu, Kimberly S. Miles, Luciano Tastaldi, Benjamin T. Miller, Lucas R. Beffa, David M. Krpata, Clayton C. Petro, Ajita S. Prabhu
The phase 3 LITESPARK-022 trial compared adjuvant pembrolizumab plus belzutifan with pembrolizumab plus placebo following resection of clear-cell renal-cell carcinoma.
